Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Office Of Women's Health Gets Permanent Director

This article was originally published in The Pink Sheet Daily

Executive Summary

Kathleen Uhl, team leader for the Pregnancy & Lactation Labeling Team, will replace Susan Wood.

You may also be interested in...



FDA Generics Office Gets Third Director In Three Workdays; Uhl Brings Policy, Pharmacology Experience

A long-time FDA veteran who remains largely unknown to the generics industry, Kathleen Uhl replaces CDER Director Janet Woodcock as acting director of the Office of Generic Drugs effective March 19 following Gregory Geba’s March 15 departure from the generic office’s top post.

FDA Women’s Health Director Resigns Over Plan B

Susan Wood says she can “no longer serve as staff when scientific and clinical evidence...has been overruled.”

Tarceva Pancreatic Cancer Indication Turned Down In The EU

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.

Topics

UsernamePublicRestriction

Register

PS061295

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel